REYVOW (lasmiditan succinate)
REYVOW (lasmiditan succinate) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine in adults. It is used to manage migraine episodes with or without aura as they occur. The medication is intended for the immediate treatment of migraine symptoms and is not indicated for the preventive treatment of migraine.
How REYVOW Works
Lasmiditan exerts its therapeutic effects by binding with high affinity to the serotonin (5-HT) 1F receptor. It acts as an agonist, meaning it activates these specific receptors to treat migraine symptoms. Although the precise biological mechanism is unknown, the drug’s efficacy is presumed to result from its agonist effects at the 5-HT 1F receptor.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2019-10-11
- Patent Cliff
- 2040
- Routes
- ORAL
- Dosage Forms
- TABLET
REYVOW Approval History
What REYVOW Treats
1 indicationsREYVOW is approved for 1 conditions since its original approval in 2019. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Migraine
REYVOW Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to REYVOW
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
REYVOW FDA Label Details
Indications & Usage
FDA Label (PDF)REYVOW is indicated for the treatment of Migraine.
REYVOW Patents & Exclusivity
Patents (4 active)
Pro Intelligence Preview
Deep insights for REYVOW
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2040
- • 33 active patents
Trial Analysis
- • 25 total trials
- • Stage: Declining
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment